Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice

Patients in real life may differ from those in clinical trials. The aim of this study is to report 5-year outcomes of a continuous treat-to-target (T2T) approach in patients with rheumatoid arthritis (RA) in daily clinical practice. In the Dutch RhEumatoid Arthritis Monitoring cohort, all patients w...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2018-05, Vol.37 (5), p.1189-1197
Main Authors: Versteeg, G. A., Steunebrink, L. M. M., Vonkeman, H. E., ten Klooster, P. M., van der Bijl, A. E., van de Laar, M. A. F. J.
Format: Article
Language:English
Subjects:
Adult
Aged
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Biological Products - therapeutic use
Clinical medicine
Clinical trials
Data processing
Drug Therapy, Combination
Female
Health risk assessment
Health Status
Humans
Male
Medicine
Medicine & Public Health
Methotrexate - therapeutic use
Middle Aged
Original
Original Article
Patient Reported Outcome Measures
Patients
Quality of Life
Remission
Remission Induction
Rheumatoid arthritis
Rheumatology
Severity of Illness Index
Sulfasalazine - therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients in real life may differ from those in clinical trials. The aim of this study is to report 5-year outcomes of a continuous treat-to-target (T2T) approach in patients with rheumatoid arthritis (RA) in daily clinical practice. In the Dutch RhEumatoid Arthritis Monitoring cohort, all patients with a clinical diagnosis of RA were treated according to a protocolled T2T strategy, aimed at 28-joint Disease Activity Score (DAS28)  5.1 (high disease activity) were 63, 16, 18 and 3%, respectively. Sustained remission (DAS28 
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-017-3962-5